The Boston Scientific Analyst: Analyst Mike Matson maintained a Buy rating, but slashed the price target from $121 to $97. The Boston Scientific Thesis: The company reported revenue of $5.286 billion ...

Despite growing sales and adjusted EPS by 16% and 14% in Q4 -- easily beating Wall Street’s estimates -- Boston Scientific stock dropped 18% on Wednesday due to “weak” guidance. More specifically, the ...

Boston Scientific grew sales and adjusted earnings per share by 16% and 14% in the fourth quarter. However, the company's guidance underwhelmed the market. Ultimately, Boston Scientific's earnings ...

Boston Scientific’s fourth-quarter profit and sales climbed but the medical-device maker issued a soft forecast for the year, sending shares down in premarket trading. The company logged earnings of ...

Penumbra expected to generate $1.4 bln in 2025 sales; shares surge 12% Transaction values Penumbra at $374 per share, 19.3% premium to last close Penumbra CEO Adam Elsesser to join Boston Scientific's ...

Boston Scientific said on Thursday it will buy ⁠medtech firm Penumbra in a deal valued at about $14.5 billion to expand its portfolio of cardiovascular devices, in the largest acquisition by the ...

Boston Scientific (BSX) on Thursday announced a definitive agreement to acquire Penumbra (PEN) in a cash and stock transaction that values the Alameda-based heart device maker at ~$14.5B, including ...

Boston Scientific has agreed to buy thrombectomy company Penumbra for about $15 billion in cash and stock in a deal that bolsters its cardiovascular portfolio. Boston Scientific on Thursday said the ...

Boston Scientific Corp. agreed to buy medical device maker Penumbra Inc. in a deal valued at more than $14 billion to expand in the treatment of blood clots and stroke. Boston Scientific said it will ...

Boston Scientific is capping off a busy week with a major buyout, entering a deal worth about $14.5 billion to acquire California-based Penumbra. The company started off the week presenting at the ...